Repurposing FDA-Approved Drugs for Treatment of 2019-nCoV-induced Disease

重新利用 FDA 批准的药物来治疗 2019-nCoV 引起的疾病

• 批准号: MC_PC_19057
• 负责人: Ultan Power
• 金额: $ 37.67万
• 依托单位: Queen's University Belfast
• 依托单位国家: 英国
• 项目类别: Intramural
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MC_PC_19057
• 关键词: Repurposing; FDA; Approved; Drugs; Treatment

SARS/CoV-2 was recently identified as the cause of the outbreak of pneumonia first detected in Wuhan, China in December 2019. Current efforts are focused on containment and separation of infected individuals, with no registered drugs for the treatment of COVID-19. Hence, drugs that have been registered for the treatment of other coronavirus conditions might be used (off-label) in an attempt to save the lives of COVID-19 patients. As development of vaccines and drugs for prevention and treatment of SARS-CoV-2 infection have been brought to priority status by WHO and governments, numerous drug studies are moving forward. Drug repurposing is defined as the application of known drugs to new indications. This approach is attractive, as repurposed drugs have already passed toxicity trials. Therefore, we aim to screen clinically approved drugs either as single or pair combinations for the therapeutic development of antiviral and anti-inflammatory agents to control and treat COVID-19 disease. We strongly anticipate the data generated will identify novel single or synergistic drug pairs, lead to detailed pre-clinical evaluation and provide the impetus for rapid progress to clinical trials or compassionate use in extreme cases.

SARS/COV-2最近被确定为2019年12月在中国武汉首次检测到肺炎的原因。当前的努力集中在遏制和分离受感染的个体上，没有注册药物治疗Covid-19。因此，可以使用已注册用于治疗其他冠状病毒疾病的药物（标签外），以挽救Covid-19患者的生命。随着谁和政府的预防和治疗SARS-COV-2感染的疫苗和药物的开发已被谁和政府提高到优先地位，许多药物研究正在进行中。药物重新利用定义为将已知药物应用于新的适应症。这种方法很有吸引力，因为重新利用的药物已经通过了毒性试验。因此，我们旨在将临床认可的药物作为单一或成对组合筛查，以控制抗病毒和抗炎药的治疗性开发，以控制和治疗COVID-19疾病。我们强烈预测，生成的数据将确定新颖的单一或协同药物对，从而导致详细的临床前评估，并为快速进步临床试验或在极端情况下的富有同情心使用。

项目成果

An Endogenously activated antiviral state restricts SARS-CoV-2 infection in differentiated primary airway epithelial cells

内源性激活的抗病毒状态限制分化的初级气道上皮细胞中的 SARS-CoV-2 感染

• DOI: 10.1101/2021.08.17.456707
• 发表时间: 2021
• 作者: Broadbent L

Evolutionary remodelling of N-terminal domain loops fine-tunes SARS-CoV-2 spike.

• DOI: 10.15252/embr.202154322
• 发表时间: 2022-10-06
• 期刊: EMBO reports
• 影响因子: 7.7
• 作者: Cantoni D;Murray MJ;Kalemera MD;Dicken SJ;Stejskal L;Brown G;Lytras S;Coey JD;McKenna J;Bridgett S;Simpson D;Fairley D;Thorne LG;Reuschl AK;Forrest C;Ganeshalingham M;Muir L;Palor M;Jarvis L;Willett B;Power UF;McCoy LE;Jolly C;Towers GJ;Doores KJ;Robertson DL;Shepherd AJ;Reeves MB;Bamford CGG;Grove J
• 通讯作者: Grove J

An endogenously activated antiviral state restricts SARS-CoV-2 infection in differentiated primary airway epithelial cells.

• DOI: 10.1371/journal.pone.0266412
• 发表时间: 2022
• 期刊: PLOS ONE
• 影响因子: 3.7
• 作者: Broadbent, Lindsay;Bamford, Connor G. G.;Lopez Campos, Guillermo;Manzoor, Sheerien;Courtney, David;Ali, Ahlam;Touzelet, Olivier;McCaughey, Conall;Mills, Ken;Power, Ultan F.
• 通讯作者: Power, Ultan F.

Comparison of SARS-CoV-2 Evolution in Paediatric Primary Airway Epithelial Cell Cultures Compared with Vero-Derived Cell Lines.

• DOI: 10.3390/v14020325
• 发表时间: 2022-02-05
• 期刊: Viruses
• 作者: Bamford CGG;Broadbent L;Aranday-Cortes E;McCabe M;McKenna J;Courtney DG;Touzelet O;Ali A;Roberts G;Lopez Campos G;Simpson D;McCaughey C;Fairley D;Mills K;Power UF;On Behalf Of The Breathing Together Investigators
• 通讯作者: On Behalf Of The Breathing Together Investigators